Business
New Two-Year Data from Pivotal ApproaCH Trial Showing Durable Benefits of TransCon® CNP (Navepegritide) in Children with Achondroplasia Shared at ACMG 2026
COPENHAGEN, Denmark, March 16, 2026 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today announced new data from its pivotal ApproaCH Trial showing that children with achondroplasia treated with once-weekly TransCon CNP (navepegritide) maintained consistent improvements in growth through Week 104, with further improvement in body proportionality during the second year of treatment. These and other results were shared in an oral presentation by Dr. Ravi Savarirayan, M.B.B.S., M.D., Murdoc
About this update from Ascendis Pharma A/s
[{"type":"image","alt":"Ascendis Pharma","displaySize":"","headline":null,"caption":"Ascendis Pharma","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":100,"url":"https://media.zenfs.com/en/globenewswire.com/7afd0e29f0a4b40bcd5ff718a81f4afe"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/1tA.9j4XDPXN.zyLsOvv6w--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTE0MDtjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/7afd0e29f0a4b40bcd5ff718a81f4afe","width":300,"height":100}},"lazy":false},{"type":"text","content":"COPENHAGEN, Denmark, March 16, 2026 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today announced new data from its pivotal ApproaCH Trial showing that children with achondroplasia treated with once-weekly TransCon CNP (navepegritide) maintained consistent improvements in growth through Week 104, with further improvement in body proportionality during the second year of treatment. These and other results were shared in an oral presentation by Dr. Ravi Savarirayan, M.B.B.S., M.D., Murdoch Children’s Research Institute (Australia), during ACMG 2026, the Annual Clinical Genetics Meeting held March 10-14 in Baltimore, Maryland.","length":640,"tagName":"p"},{"type":"text","content":"“Two-year data from the ApproaCH Trial demonstrated continued improvement in body proportionality and sustained increases in linear growth,” said Professor Savarirayan. “In addition, children switching from placebo to TransCon CNP at Week 52 demonstrated one-year results that mirrored those previously reported in three randomized double-blind, placebo-controlled trials of TransCon CNP, highlighting its potential as a transformative once-weekly treatment option for children with achondroplasia.”","length":499,"tagName":"p"},{"type":"text","content":"TransCon CNP is a prodrug of C-type natriuretic peptide (CNP) administered once weekly, designed to provide continuous exposure of active CNP to receptors on tissues throughout the body to counteract the overactive FGFR3 signaling in achondroplasia. In February 2026, TransCon CNP was approved by the U.S. FDA under the trade name YUVIWEL® to increase linear growth in pediatric patients 2 years of age and older with achondroplasia with open epiphyses. The Marketing Authorization Application for YUVIWEL is under review by the European Medicines Agency with a regulatory decision anticipated in ...